Backbone modified oligonucleotide analogues
US6900301B2 · kind B2 · utility
12Cited by
14References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2002 |
| Grant date | May 31, 2005 |
| Priority date | — |
| Expiry date | Jun 12, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H21/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic oligonucleotide analogues which have improved nuclease resistance and improved cellular uptake are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligomers with four atom linking groups forms unique di- and poly-nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.